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Addressing obesity in the management of
knee and hip osteoarthritis – weighing in
from an economic perspective
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Abstract
Background: Obesity is one of the only modifiable risk factors for both incidence and progression of Osteoarthritis
(OA). So there is increasing interest from a public health perspective in addressing obesity in the management of
OA. While evidence of the efficacy of intereventions designed to address obesity in OA populations continues to
grow, little is known about their economic credentials.
The aim of this study is to conduct a scoping review of: (i) the published economic evidence assessing the
economic impact of obesity in OA populations; (ii) economic evaluations of interventions designed to explicitly
address obesity in the prevention and management of OA in order to determine which represent value for money.
Besides describing the current state of the literature, the study highlights research gaps and identifies future
research priorities.
Methods: In July 2014, a search of the peer reviewed literature, published in English, was undertaken for the period
January 1975 – July 2014 using Medline Complete (Ebscohost), Embase, Econlit, Global Health, Health Economics
Evaluation Database (HEED), all Cochrane Library databases as well as the grey literature using Google and
reference lists of relevant studies. A combination of key search terms was used to identify papers assessing the
economic impact of obesity in OA or economic evaluations conducted to assess the efficiency of obesity
interventions for the prevention or management of OA.
Results: 14 studes were identified; 13 were cost burden studies assessing the impact of obesity as a predictor for
higher costs in Total Joint Arthroplasty (TJA) patients and one a cost-effectiveness study of an intervention
designed to address obesity in the managment of mild to moderate OA patients.
Conclusion: The majority of the economic studies conducted are cost burden studies. While there is some
evidence of the association between severe obesity and excess hospital costs for TJA patients, heterogeneity in
studies precludes definitive statements about the strength of the association. With only one economic evaluation
to inform policy and practice, there is a need for future research into the cost-effectiveness of obesity interventions
designed both for prevention or management of OA along the disease spectrum and over the life course.
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Background
Obesity poses one of the greatest contemporary global
public health challenges. Worldwide, the number of over-
weight or obese individuals has more than doubled since
1980 [1]. With rising prevalence rates in adult popula-
tions, the consequential growth in obesity-related chronic
disease, including osteoarthritis (OA), is inevitable. Glo-
bally, the prevalence of OA, particularly of the large
weight-bearing joints such as the knee and hip, is also pre-
dicted to grow [2], spurred on as a result of an ageing
population but also an ageing population that is getting
heavier [2].
There is well established evidence associating obesity
(BMI ≥ 30 kg/m2 [3]) and OA, with obesity being identi-
fied as a major but modifiable risk factor for both OA
disease incidence and progression [4–6]. The issue with
obesity and OA is that the two conditions often coin-
cide, working synergistically to perpetuate poor function
and a greater likelihood of sedentary lifestyles which
inevitably lead to higher levels of disability and a reduc-
tion in quality of life [7]. Furthermore, the need for total
joint arthroplasty (TJA) surgery for the treatment of se-
vere OA in knees and hips is more likely to arise in the
obese [8] and earlier in life [9]. Changulani et al. 2007
reported that patients with a BMI of >35 kg/m2 who
were treated by knee replacement were, on average,
13 years younger than their normal weight counterparts;
the authors alluded to the potential implications of
younger age for lifetime management of OA [9]. Wang
et al. 2013 also highlighted that weight gain and persist-
ent excess weight from early adulthood increased the
risk of TJA of the hip and knee for OA [10].
Knee and hip OA is one of the leading causes of global
disability and was ranked as the 11th highest contributor
to global disability in the most recent Global Burden of
Disease study in 2010 [2]. As such, OA as a disease
results in large indirect costs to society, mostly driven by
impacts on productivity [11]. These indirect costs, when
coupled with rapid growth in direct healthcare related
costs associated with management of the disease and
specifically TJA as a major cost driver [12], mean that
the economic burden is huge. Furthermore, it is likely to
be exacerbated by the aforementioned growing obesity
and OA prevalence. Despite TJA being a very effective
and cost-effective treatment option for end stage hip
and knee OA, 2013 data from the Organisation for
Economic Co-operation and Development (OECD) high-
lights continuing growth in the number of procedures
being carried out with faster growth in knee replace-
ments (TKA) particularly in countries with higher rates
of overweight and obesity such as Australia, USA and
the UK. It has been estimated that in 2007 in Australia,
allocated health care expenditure on OA alone was
approximately AUD 2 billion [13]. However, given that
obesity rates are likely to continue to rise, this will
potentially lead to substantial increases in the prevalence
of OA and an even greater burden on health care expend-
iture [13].
There is now a substantial body of evidence focusing on
the relationship between obesity and OA from a variety of
perspectives. This includes investigation of the causal rela-
tionships of obesity and OA through biomechanical [14],
physiological [15] and inflammatory mechanisms [16] and
quantification of the impact of obesity on OA outcomes
[14]. Attention has also been afforded to the benefits of
weight loss in OA populations including a systematic
review which concluded that a 10 % reduction in body
weight is likely to have positive clinically meaningful
effects on OA symptoms such as pain and disability [17].
A recent review focused on addressing obesity in knee
OA, identified 9 randomised controlled trials of weight
loss interventions in people with knee OA. It concluded
that there are several strategies likely to be successful in
the management of knee OA [18]. However, the evidence
base is far from definitive in terms of what is the most
efficacious type of intervention, who it should specifically
target and when along the treatment pathway it should be
offered. There are the usual challenges of whether obesity
interventions can achieve long term weight maintenance
and prevent weight regain [19], particularly in a popula-
tion where OA symptoms may hinder physical activity
efforts. There is also some concern that interventions that
target weight loss alone may lead to muscle weakness and
some bone density loss [20], meaning that an intervention
that targets both weight loss and appropriate physical
activity simultaneously is likely to be more favourable.
This is reflected in current treatment guidelines recom-
mending that weight maintenance and exercise in com-
bination are suitable for managing OA symptoms [21, 22],
although, in reality, it is often difficult to determine com-
pliance with these recommendations.
Despite this apparent research momentum, it is not clear
what the contribution of research from a health economics
perspective has been in terms of supporting the use of
obesity interventions in the prevention or management of
OA. The discipline of health economics is fundamentally
concerned with the allocation of scarce healthcare re-
sources in an environment of competing demands with the
goal of maximising a society’s welfare in the process [23].
Health economists typically carry out two different types of
studies designed to achieve different purposes. Firstly, they
describe and predict the economic impact of a disease or
risk factor in order to quantify its cost burden (commonly
known as cost of illness studies); secondly, they evaluate
the incremental costs and benefits of alternative options to
current practice (cost-effectiveness studies) [24] to inform
resource allocation decisions. The latter essentially ad-
dresses the main objective of economics per se, that being
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efficiency, or maximising the benefit from available
resources.
The goals of this study are two-fold. Firstly, it aims to
identify and review the published economic evidence that
is focused on describing and quantifying the economic
impact of obesity in OA populations. Secondly, it reviews
economic evaluations of interventions designed to expli-
citly address obesity in OA populations in order to pre-
vent the onset of OA or improve OA clinical outcomes
and potentially health related quality of life (HrQoL), to
determine which interventions represent value for money.
In doing so, the study also highlight gaps in the literature
and identifies future priorities for this burgeoning area of
research.
Methods
Literature search strategy
A systematic search of the published peer reviewed litera-
ture was conducted in July, 2014 by the lead author. The
search was limited to full text literature published in the
English language from January 1975 – July 2014. Six elec-
tronic databases were searched: Medline complete (Ebsco-
host), Embase, Econlit, Global Health, Health Economics
evaluation database (HEED) and all Cochrane Library
databases using the same search terms and Boolean opera-
tors in each database. Key words used and search combi-
nations were as follow: osteoarthritis or arthritis or joint
replacement or joint prosthesis or arthroplast* or knee
arthroplasty or hip arthroplasty AND obes* or obesity or
overweight or weight gain or weight loss or BMI or body
mass or weight* or weight control AND prevention or
treatment or primary prevention or secondary prevention
AND economic* or economic evaluation or price or cost
or cost-effectiveness analysis or economic benefits or cost
benefit analysis or cost burden. A targeted Google search
of the grey literature using the search terms was con-
ducted, plus the reference lists of all relevant articles were
searched for further studies.
Study selection
All relevant abstracts obtained from each database were
exported to ENDNOTE, X7 (Thomson Reuters) with
duplicate articles removed. Titles and abstracts were
searched and relevant full -articles, extracted and
reviewed (see flow chart, Fig. 1). For inclusion, studies
had to fulfil one (or more) of the three following broad
criteria:
1. A costing or cost of illness study which evaluates the
association of obesity in any OA study population
with healthcare or other societal costs.
2. A partial economic evaluation study which assesses
either the costs alone or the costs and outcomes of
an obesity intervention in any OA study population
but without comparison to an alternative healthcare
pathway (cost description or cost-outcome
description) or where the costs of alternatives are
examined but without consideration of outcomes
simultaneously (cost analysis). An obesity
intervention was defined as any intervention that
included a component that addressed weight loss or
weight maintenance in order to impact on OA
symptoms and outcomes.
3. A full economic evaluation study such as a
cost-effectiveness analysis, cost utility analysis or
cost benefit analysis which assesses both the costs
and benefits of an obesity intervention against a
known alternative or usual care in any OA study
population.
The three criteria were purposely broad given that this
is a scoping review designed to find any relevant studies
and highlight gaps in the literature.
Results
Figure 1 identifies all steps in the search process and the
resulting studies extracted. In the first instance, 2048
citations were retrieved from searched databases (1997)
and other sources (51). After removal of duplicates and
irrelevant citations, 215 abstracts of candidate articles
were screened of which 71 full text articles were assessed
for eligibility. The search yielded 12 costing studies
(Table 1) and one full economic evaluation (Table 2).
Impact of obesity on resource use studies in TJA
populations
Settings and target group
There were twelve studies identified as cost burden studies;
they all included analysis of the association between the
presence of obesity in total joint replacement populations
used as a predictor of healthcare costs [25–36]. Nine stud-
ies were set in acute care hospitals with a focus on THA
[26, 31, 36] or TKA recipient populations [30, 33, 35] or
included both THA and TKA recipients [25, 32, 34]. The
remaining three studies were set in inpatient rehabilitation
hospitals with two studies focusing on TKA recipients
[27, 29] and one on THA recipients [28]. Table 1 summa-
rises the main characteristics of the identified studies. They
included a mix of studies focusing on primary or index TJA
surgery only [25, 26, 30–33] or inclusion of both primary
and revision types of surgeries [27–29, 34–36]. This high-
lights the heterogeneity between studies in relation to the
specific populations under study, with each having its own
unique set of patient inclusion and exclusion criteria.
Nearly all studies were conducted in the USA with only
one study conducted in Australia [33].
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Costs
All studies, regardless of setting, were conducted retro-
spectively from a narrow healthcare perspective and were
restricted to the collection of direct medical costs or
charges specific only to that setting. All studies relied on
hospital administration data. While this enabled most of
the studies to have near complete data, the downside was
that the costs reported in each study were limited and did
not reflect the total cost burden. As an example, the studies
conducted in the acute care setting took no account of
costs of the resources consumed in rehabilitation, support-
ive nursing facilities, outpatient and ambulatory care ser-
vices or costs borne either by other sectors or by patients
themselves. Methods used for identification, measurement
and reporting of cost outcomes were heterogeneous and
not always transparent; some studies provided little detail
about their costing methodology including the selection or
specification of cost items included in reported aggregate
resource use [27, 28, 32] or the reference year used for the
costing [27, 28]. Some studies only presented hospital
charges rather than costs per se [26–29], the former usually
reflecting an element of profit as well as a method of
recouping uncompensated costs. If this profit is considered
above and beyond the societal opportunity cost, then ad-
justments should be made with cost to charge ratios [37].
However the choice of ratio applied (eg. the use of an over-
all hospital ratio versus a department specific ratio) varied
between studies and introduced an element of uncertainty
in the estimates obtained. The timeframe over which re-
source use was measured also varied greatly between stud-
ies. Some studies only accounted for hospital resource use
during inpatient stay post -surgery [25–29, 32]. Others
sought to capture resource use related to potential readmis-
sions by measuring up to 30 days [30, 31, 34] or three
months post -surgery [35, 36]; only one study followed
patients for 12 months post- surgery in order to capture a
Fig. 1 Search flowchart. OA Osteoarthritis, TJA Total Joint Arthroplasty
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Table 1 Studies assessing the impact of obesity on resource use in total hip or knee arthroplasty
Author,
Year
Healthcare
setting/
Country
Study population Research aim/focus Measurement
of obesity
Costing perspective/
measurement and
types of counted
Results
Epstein
AM, et al,
1987 [25]
Large acute
care hospital,
USA
278 patients who
underwent TKA
and 111 patients
who underwent
THA, October
1983 -September
1984.
To determine the
relationship of body
weight to LOS and
total charges for all
patients undergoing
THA or TKA
Height and weight taken
from pre-operative medical
records.
5 levels of weight status
categorised by actual
weight compared to
ideal weight as a %
Health service provider
perspective capturing
charge data for the
inpatient stay only.
Extremely overweight patients
(≥ 188 % ideal) had 35 % mean longer
LOS (p < 0.01) and 30 % higher total
charges (p < 0.01) than normal weight
counterparts. Extremely underweight
patients also reported significantly
higher costs.
Jibodh SR,
et al, 2004
[26]
Large acute
care hospital,
USA
188 patients
who underwent
primary THA,
1996 – 2001.
To determine the
influence of BMI
on perioperative
morbidity (time
of surgery until
discharge) on
functional recovery
and hospital
service use (LOS,
total and individual
cost items)
Height and weight taken
from pre-operative medical
records to calculate BMI
and categorised into non
obese(BMI < 25), mild
(BMI >25-29.9), moderate
(BMI>30-39.9) and severe
(BMI >40)
Health service provider
perspective using
hospital charge data
and reporting total
charges and 8 separate
billing categories
No significant difference in LOS between
4 BMI groups. A trend towards higher
overall charges with increasing obesity
but not statistically significant. No
significant differences in any of the
individual charges were noted between
4 BMI groups in any of 8 billing categories,
however morbidly obese patients longer
mean operative time (P < 0.05)
Vincent HK,
et al, 2007
[27]
Inpatient
rehabilitation
hospital, USA
342 participants
who underwent
primary or
revision TKA,
January 2002 -
March 2005.
Complete case
analysis on 285
participants.
To examine the
effect of obesity
on functional and
financial
outcomes in
patients with TKA
undergoing
inpatient
rehabilitation.
Height and weight taken
from patient medical
records to determine BMI
and categorised as obese
(BMI > 30) or non-obese
(BMI < 30)
Health service provider
perspective using
hospital charge data
collecting total hospital
charges and daily
charges for period of
inpatient stay only.
LOS was longer in primary
and revision obese patients (9.8 days)
than for non- obese patients (8.8 days)
(P < 0.05). Total charges were higher
for obese patients (USD 12,386) than
non -obese patients (USD 10,618)
(P < 0.005). Primary TKA group; total
hospital charges were significantly
higher in the obese than non- obese
group (P < 0.05)
Vincent HK
et al, 2007
[28]
Inpatient
rehabilitation
hospital, USA
339 obese and
non- obese
patients with
primary or
revision THA,
January 2002-
March 2005.
Complete case
analysis on 178
participants.
To examine the
effect of
increasing BMI on
functional and
financial
outcomes in
patients with THA
undergoing
inpatient
rehabilitation
Height and weight taken
from patient medical
records to determine BMI
and categorised as
non- obese (BMI < 25)
overweight (BMI 25-30)
obese (BMI > 30-39.9)
and severely obese
(BMI≥ 40)
Health service provider
perspective collecting
total hospital charges
and daily charges
(using total charges
and dividing by LOS)
for the period of the
inpatient stay only.
LOS were significantly different in the
severely obese group compared with
the non- obese group (p < 0.05). A
significant curvilinear relationship
between LOS and BMI with the lowest
LOS found in overweight and obese
persons (R squared =0.124 P < 0.05).
Total charges were greater in the
severely obese group compared to
the overweight group (P < 0.05).
Vincent HK
& Vincent
KR, 2008
[29]
15
independent
rehabilitation
hospitals,
USA
5428 obese
and non-obese
patients who
underwent
primary TKA or
revision TKA,
January 2002-
March 2006.
To determine the
influence of
obesity on
rehabilitation
outcomes
including LOS
and hospital
Height and weight taken
from patient medical
records to determine
BMI and categorised as
non-obese (BMI < 25)
overweight (BMI 25-30)
obese (BMI > 30-39.9)
Health service provider
perspective with collection
of total charges and
pharmacy, occupational
and physical therapy
rehabilitation hospital
charges
LOS was longest in the non- obese
group compared to all other groups
(P < 0.05) but age differences amongst
groups likely to be impacting on results.
The severely obese group had the
highest daily charges (USD 36 excess
dollars) (p < 0.05) but not physical therapy
charges or total charges which was highest
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Table 1 Studies assessing the impact of obesity on resource use in total hip or knee arthroplasty (Continued)
charges
following TKA
and severely obese
(BMI≥ 40)
in the non -obese group (P < 0.05). A
significant interaction effect was
found for TKA status (primary versus
revision) and BMI group for total
charges (P < 0.05).
Batsis JA,
et al, 2010
[30]
Large acute
care hospital,
USA
5539
uncomplicated
TKA recipients,
1996- 2004 and
classified by BMI
(WHO) categories.
To determine the
impact of BMI on
post-operative
outcomes and
resource utilization
following elective
TKA
Height and weight taken
at time of surgery and
recorded in own joint
registry to determine
BMI and categorised as
BMI normal (BMI 18.5-
24.9) overweight (BMI
25-29.9) obese (BMI >
30-34.9) and morbidly
obese (BMI ≥ 35.0)
Health service provider
perspective with all direct
costs associated with
inpatient stay including
physician services and
readmission within 30 days
associated with the primary
surgery.
Overall costs were similar among normal,
overweight, obese or morbidly obese
patients (P = 0.24) Post-surgical costs were
no different among groups (P = 0.44).
Higher BMI was associated with a higher
mean anaesthesia and operative times and a
higher overall Charlson comorbidity index.
Batsis JA,
et al, 2009
[31]
large acute
care hospital,
USA
5642 unilateral
uncomplicated
THA patients
between
1996 -2004 and
classified by BMI
categories.
To determine the
impact of BMI on
post-operative
outcomes and
resource utilization
following elective
THA
Height and weight taken
at time of surgery and
recorded in own joint
registry to determine
BMI and categorised as
BMI normal (BMI 18.5- 24.9)
overweight (BMI 25-29.9)
obese (BMI > 30-34.9) and
morbidly obese (BMI ≥ 35.0)
Health service provider
perspective with all direct
costs associated with
inpatient stay including
physician services and
readmission within 30 days
associated with the primary
surgery.
No significant differences between BMI
groups for LOS, post-operative overall,
hospital and physician costs. Operative and
anaesthesia costs were higher in morbidly
obese group than all other groups. All
other adjusted costs were non-significant.
No significant differences between groups
in: composite 30 day endpoints, rate of
patient transfers to ICU or number of days
in ICU.
Kim, SH,
2010 [32]
Short stay, community
hospitals in the
Nationwide Inpatient
Sample (NIS- 2006),
USA
229 001 primary
TKA recipients
and 497 001
primary THA
recipients in the
USA captured in
the NIS.
To estimate the
prevalence of
morbid obesity
(≥40 kg/m2 in
the THA and TKA
sample and to
determine if there
is greater resource
use attributable
to morbid obesity
for primary TJA
Presence of obesity (BMI
≥30.0) and morbid obesity
(BMI≥ 40.0) identified by
the corresponding ICD_9M
codes for obesity in
hospital administrative
databases
Health service provider
perspective using hospital
inpatient charge data
converted to cost data and
reporting on overall
hospital costs only
When adjusted for known confounders,
hospital resource consumption for primary
THA and TKA was 9 % and 7 % higher
among morbidly obese than among
non-obese patients respectively
Dowsey M,
et al, 2011
[33]
Large acute
hospital, Australia
521 primary TKA
recipients, January
2006 - December
2007.
To determine
whether obesity
was independently
associated with
higher hospital
costs for the
index procedure
and over the
following 12
months.
Presence of obesity (BMI
≥30.0) captured from
preoperative measures
recorded in own
hospital joint registry
Healthcare service provider
perspective capturing total
inpatient costs for the index
TKA, relevant
readmissions in
the first 12 months
and the
two together named
episode of care.
Statistically significant association between
obesity and higher inpatient costs
($1127 P = 0.036) and higher episode of
care costs (+1,821 P = 0.024). Using BMI as
a continuous variable, cost of index
procedure increased by $129 and episode
of care costs increased by $159 per unit
increase of BMI.
Silber JH,
et al, 2012
[34]
47 acute
hospitals of
varying size
2045 obese
patients
(BMI≥ 35 kg/m2)
To study the medical
and financial
outcomes associated
Presence of severe
obesity
(BMI≥ 35.0 < 40.0) and
Healthcare service
provider perspective
using 2 alternate
Medicare payments were 3 % greater
(P < 0.001) and provider costs were 10 %
greater for obese compared to non- obese
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Table 1 Studies assessing the impact of obesity on resource use in total hip or knee arthroplasty (Continued)
across multiple
locations, USA
matched to
non-obese
patients
undergoing THA,
TKA (primary or
revision),
colectomy,
thoracotomy,
2002- 2006. 75 %
of the sample
underwent TJA.
with surgery in
the elderly obese.
morbid obesity (BMI ≥ 40.0)
captured from baseline BMI
data in hospital medical
records
costing methods
(Medicare payments
versus costs using
cost to charges ratios)
(to determine overall
hospital costs from
admission to 30 days
post operation.
matched counterparts (P < 0.001). The Obese
group recorded a 12 % longer LOS than
their complete matched non obese
counterparts (P < 0.001)
Maradit
Kremers H,
et al, 2014
[35]
Large acute
care hospital,
USA
8129 patients
who underwent
6475 primary TKA
and 1654 revision
TKA, January 2000 -
September 2008.
To examine the
relationship between
obesity, length of
stay and direct
medical costs during
the index
hospitalisation and a
90 day window
taking into account
obesity related
co-morbidities.
Height and weight taken
from patient admission
records to calculate BMI
and categorised into 8 BMI
categories and as a
continuous variable
Health service
provider
perspective using
hospital
administration
databases and
converting charges
to costs using cost
centre specific ratios.
End points of hospital
LOS, direct medical
costs during
hospitalisation and
total medical costs
during the 90 day
window
LOS was longer at the extreme ends of the
BMI spectrum only with mean LOS lowest in
those with BMI 30-40.0.
After adjusting for known confounders,
every 5 unit increase in BMI over 30 was
associated with higher mean costs of USD
421 for hospitalisation and USD 524
for 90 days and remained significant after
adjustment for comorbidities (P = <0.001)
and complications (P = 0.004).
Maradit
Kremers H,
et al, 2013
[36]
Large acute
care hospital,
USA
8973 patients;
6410 primary
THA and 2563
revision THA's,
January 2000 -
Sept 2008.
To examine the
relationship between
obesity, length
of stay and
direct medical
costs during the
index hospitalisation
and a 90 day
window taking into
account obesity
related
co-morbidities.
Height and weight taken
from patient admission
records to calculate BMI
and categorised into 8 BMI
categories and as a
continuous variable
Health service
provider perspective
using hospital
administration
databases and
converting charges
to costs using cost
centre specific ratios.
End points of hospital
LOS, direct medical
costs during
hospitalisation and
total medical costs
during the 90 day
window
Increasing BMI was associated with higher
hospital costs and this association persisted
among patients without significant
comorbidities or complications. After
adjusting for known confounders, every 5
unit increase in BMI was associated with
USD 744 and USD 1183 higher
hospitalisation and 90 day costs respectively.
(This corresponds to about 5 % higher
hospitalisation and 90 day costs
respectively).
TKA total knee arthroplasty, THA total hip arthroplasty, TJA+ total joint arthroplasty, LOS length of stay, BMI body mass index, USD USA dollars, NIS national inpatient survey, ICD-9 M The International Classification of
Diseases, 9th Revision
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Table 2 Economic evaluation of obesity interventions in OA populations
Author, Year,
Country
Intervention Target population Type of economic
evaluation, time
horizon
Costing perspective, costs
included, base year for
costing
Outcome
measurement
Costs Cost- efficacy
Sevick MA,
et al, 2009
[38]
18 month dietary and
exercise intervention in
overweight/obese
elderly patients with
knee OA The ADAPT
trial - 4 arms in the trial:
healthy lifestyle control,
diet, exercise, exercise
and diet.
participants aged≥ 60
year, BMI≥ 28 kg/M2,
with radiographic
evidence of knee OA
(but not advanced stage
radiographic evidence)
Cost-efficacy
study over 18
months; no
modelled analysis.
Managed care
organisation payer
perspective. Intervention
costs (staff time, facilities,
equipment and materials)
collected prospectively
and self- reported health
services consumed by
participants over the
duration of the trial. All
costs adjusted to Yr. 2000
USD
WOMAC (function,
pain, stiffness
components separately),
weight change, 6 MWT
and stair climb.
Total intervention costs
and health service
utilisation costs in USD
per participant per
month: control: $32,
Diet only: $160, Exercise
only: $152, Exercise and
Diet:$304
Exercise and diet intervention
most cost effective for improved
self-reported function, pain and
stiffness (USD 24 per PPI in
function, USD 20 per PPI in pain,
USD 56 per PPI in stiffness)
compared to healthy control.
Diet arm was most cost effective
for reducing weight (USD 35 per
PPR in baseline body weight)
ADAPT arthritis, diet and physical activity promotion diet, BMI body mass index, WOMAC Western Ontario and McMaster Universities Arthritis Index, 6 MWT 6 min walk test, USD US dollars, PPI percentage point
improvement, PPR percentage point reduction, OA osteoarthritis, PPI percentage point increase
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picture of the annual hospital resource use as impacted by
the presence of obesity [33].
Obesity measurement
The studies varied in terms of ascertaining and classifying
the presence of obesity in the study population. In Epstein
et al [25], the earliest study, obesity was measured as the
relative weight to normal weight which is now considered
an outdated method for classifying obesity; all the other
studies used Body Mass Index (BMI) categories and/or
BMI as a continuous variable although there was variation
between studies as to the number and cut offs for the
BMI categories used. Nearly all identified studies used
recorded height and weight data obtained from medical
records as the basis of BMI calculations. However the
Kim et al. study that analysed a sample of 229 001 TKA
recipients and 497 001 THA recipients captured in the US
Nationwide Inpatient sample (NIS), used hospital admin-
istration coded data to determine the presence or absence
of obesity rather than the height and weight recorded
body measurements of patients per se [32]. This opened
the study to misclassification bias and it has also been
suggested in the literature that administrative data under-
reports the presence of obesity [36].
Analytical approach
The main variation in analytical approach between studies
was whether an analysis conducted accounted for the
presence of obesity related co-morbidities as a potential
mediator or confounder between obesity and hospital
costs. More recent studies were more likely to present
results of both unadjusted and adjusted analyses using
well known comorbidity indexes to show both the medi-
ated and independent effect of obesity on hospital costs.
Kremers et al [35], stated that obesity is a risk factor for
several costly comorbidities and, therefore, controlling for
co-morbidities may result in underestimation of the true
incremental cost of obesity because costs attributable to
comorbidities theoretically can be considered attributable
to obesity.
Results
Given such heterogeneity in elements of study design,
including study setting, sample size, population under
study, measurement of key variables and the analysis
performed, it is not surprising that results of those studies
are somewhat mixed. Three studies suggest there is no
difference between groups by BMI categories on hospital
costs in the acute care setting [26, 30, 31]. The remaining
six acute care setting studies found a statistically signifi-
cant association between the presence of severe obesity
(>35 kg/m2) and higher health care costs/charges with the
difference mostly in the range of 5-10 %. Overall, the more
recent studies, with larger sample sizes and longer follow
up periods tended to present positive association results.
The main driver of the cost difference was overall hospi-
talisation costs, although length of stay (LOS) related to
the primary episode of care, was not always identified as a
contributing factor to these higher costs.
Whilst Epstein et al. reported 30 % higher total charges
and 35 % mean longer LOS for persons classified as ex-
tremely overweight (body weight ≥ 188% of ideal) compared
to their normal weight counterparts [25], the costs pre-
sented were high and less relevant today given the recent
introduction of more streamlined and efficient clinical care
pathways.
The two single centre rehabilitation studies [27, 28]
reported that severe obesity in both THA and TKA popu-
lations was associated with higher overall hospital charges.
However, results of the much larger multicentre trial in
the TKA population contradicted the results of the single
site study by reporting that whilst the severely obese had
the highest daily charges of all BMI groups (albeit modest
at USD10-36 per day), total charges were highest in the
non obese group. The authors cautioned interpretation of
these results, given that the average non obese patient was
11.2 years older than those in the severely obese group,
indicating that age-related changes could be driving the
costs. The authors also reported a significant interaction
effect between high BMI and revision surgery leading to
prolonged and more costly inpatient care.
Cost-effectiveness studies
Results of the literature search revealed only one full eco-
nomic evaluation. The latter was a within trial cost-
effectiveness analysis (CEA) study by Sevick et al, 2009
[38], run alongside the ADAPT trial (Arthritis, Diet and
Physical Activity Promotion Trial) [39] which followed
316 participants with moderate knee OA and baseline
BMI of ≥ 28 kg/m2, randomised to one of 4 arms: healthy
lifestyle control, diet alone, exercise alone or diet and
exercise interventions delivered over 18 months. Key
study design characteristics and results of this economic
evaluation are summarised in Table 2.
The study provides evidence that a multimodal inter-
vention incorporating both physical activity and diet com-
ponents is the most efficient choice for improving self-
reported function, pain and stiffness as measured using
the 3 Western Ontario and McMaster Universities Osteo-
arthritis Index (WOMAC).
Sub-scales at 18 months compared to a healthy life-
style control or diet and exercise interventions alone.
However, it was not the most efficient choice for weight
loss alone or for functional measures of mobility alone.
The authors suggest that the magnitude of change in
WOMAC scores found in the exercise and diet group
could be considered clinically significant in similar Knee
OA populations [38]. Despite the reported comparative
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efficiency of the multimodal intervention arm, the total
costs of the ADAPT intervention arms were higher than
other CEAs of exercise and other conservative interven-
tions in general OA populations [40–43]; this reflects the
resource intensive nature of the intervention design and
delivery over the 18 month trial duration. While the
authors concluded that both weight loss and physical
activity are needed to achieve improvements in subjective
physical function and pain, it is not clear whether a diluted
approach would necessarily achieve the same results.
There are some limitations to this study that are ac-
knowledged by the authors. Costing was performed from
a narrow managed care as health care provider perspec-
tive. For example, it did not include patient out of pocket
costs such as the cost of pharmaceuticals which are likely
to be impacted, particularly if pain and function is im-
proved by the intervention. Other costs that would be in-
cluded from a societal perspective such as productivity
impacts were likewise excluded. The time horizon was
also limited to the duration of the trial. Longer term fol-
low up of both costs and outcomes would have provided
greater understanding of whether the intervention could
maintain function in the long term, prevent disease pro-
gression and the associated impact on healthcare resource
use over this time. The study population for this evalu-
ation was overweight and obese patients with knee OA
but not end stage OA with an average baseline BMI of ≥
28 kg/m2. However exercise maybe more difficult in end
stage OA populations and there is also debate about
whether exercise is actually beneficial at higher BMI’s
(≥35 kg/m2) until weight loss is first achieved [4].
Discussion
Despite a growing body of literature highlighting the im-
portance of addressing obesity in OA populations, this
review highlights the current paucity of economic evalu-
ation research conducted in this area. Therefore, it remains
unclear as to whether it is efficient to address obesity expli-
citly for the prevention or management of OA, how to best
do it, which population to target, and when along the
disease spectrum this should occur.
Nearly all studies identified were cost burden studies
in TJA populations conducted to assess whether obesity
leads to higher healthcare sector costs. It should also be
noted that all of identified the studies related to OA in
knees and hips, despite the search of OA being much
broader. All of the costing studies adopted the narrow
perspective of the individual healthcare setting from
which the main cost data were derived; therefore, they
did not account for costs associated with the whole con-
tinuum of care for TJA and only provided a snapshot of
the potential economic impact compared to if a societal
approach had been taken. With greater streamlining of
acute health care clinical pathways for joint replacement
recipients, some of the traditional post-operative costs have
shifted away from the acute care setting and onto inpatient
rehabilitation, outpatient, community and ambulatory care
settings as well as patients and families themselves. Ideally,
resource use should be tracked throughout the whole
episode of care, using database linkage to gain a broader
understanding of the costs associated with the presence of
obesity in TJA populations. A Canadian study by Tarride et
al [44] which tracked total healthcare resource use in both
hospital and ambulatory care settings (though not OA
attributable costs per se), demonstrated that healthcare
costs per year to OA patients were nearly double those of
non OA control participants. A subsequent finding that
was not the primary objective of the study was that costs
were more than triple for obese OA patients compared to
non-obese controls; this highlights that the co-existence of
obesity and OA possibly augments the excess financial bur-
den of OA.
Not all of the costing studies reviewed concluded that
higher costs in TJA populations were due to obesity per se.
However, the more recent studies with stronger method-
ologies trended towards showing significant differences in
healthcare costs between the severely obese compared to
other BMI categories, which suggests that there are
potential health care cost savings to be realised if weight
loss in the severely obese is addressed prior to TJA surgery.
Yet focusing only on the cost side of the equation simply
identifies a potential problem, but does not address issues
of technical (“how to do”) or allocative efficiency (“what to
do”) in terms of choosing alternate healthcare programme
options; these can only be addressed by economic evalu-
ation studies. Similarly, establishing and subsequently
investing in interventions with proven efficacy alone with-
out consideration of the cost implications will inevitably
drive healthcare spending upwards [45]. For example, there
is increasing interest in the use of laparoscopic adjustable
gastric banding surgery, for severely obese (BMI ≥ 35 kg/m
2) to achieve rapid weight loss prior to TKA [46] given
some evidence of negative health outcomes post TKA for
these patients such as higher rates of infection [47], higher
rates of revision [47], and worse pain and function post
operatively [48]. Lap band surgery is highly efficacious [49,
50] and cost-effective [50, 51] as a weight loss intervention
in the severely obese but it is also a very costly intervention.
It remains to be seen whether the incremental cost of add-
ing this procedure prior to TJA in this population is out-
weighed by the incremental benefits achieved through cost
offsets and improved health outcomes including health
related quality of life gains immediately post-surgery and
over longer time periods. It is certainly worthy of further
investigation however, given evidence of the association of
pre-operative obesity predicting additional weight gain post
TJA [52] which is only likely to further precipitate the ill
effects of OA and obesity in combination.
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Only one economic evaluation was identified in this
review [38]. This showed that despite a small but growing
number of efficacy trials that have been conducted to
assess the impact of interventions to address obesity in
OA populations [18], published cost-effectiveness studies
are still lacking as in many areas of obesity research. The
Sevick et al study, provided some evidence that weight
loss and exercise in combination was most cost-effective
in improving pain and function in overweight and obese
patients with moderate knee OA compared to only exer-
cise or weight loss independently. Yet the study provides
no indication of the intervention’s longer term cost-
effectiveness beyond the 18 month trial duration. It would
be of particular interest to a range of stakeholders (clini-
cians, funders and patients) to know if the intervention
was able to slow disease progression, control symptoms
and maintain function for longer in persons with obesity
and OA and subsequently delay their demand for more
intensive and costly healthcare that coincides with higher
levels of disability. Longer term cost-effectiveness studies
however are reliant on either longer duration efficacy
studies being conducted or, alternately, extrapolation of
outcomes through modelling; the latter can be very
informative but are dependent on assumptions especially
in relation to maintenance of program effect. It would also
be interesting to see how changes in OA symptoms as a
result of an intervention manifests in terms of the quality
of life impact using a utility-based HRQoL measure that
can be used in economic evaluation to produce a cost per
Quality Adjusted Life Year (QALY). QALYs provide a
common generic measure of benefit taking into account
both mortality and morbidity impacts and importantly,
within this context, may capture benefit from weight loss
and exercise that extends beyond that of the effect on
immediate OA related outcomes. This metric also facili-
tates comparison of the cost effectiveness of interventions
within and across disease areas. Even if studies have not
incorporated a generic utility based HRQoL measure,
there are reliable mapping techniques available. For ex-
ample mapping techniques have been used to map disease
specific measures such as the WOMAC to HRQoL scores
on measures such as the EQ-5D [53] and the Assessment
of Quality of Life (AQoL) [54] for Australian populations,
although there are some limitations to the applicability of
such mapping exercises [54].
With only one published cost-effectiveness study to
inform policy and practice in this area, it is evident that
there is a need for more economic evaluations of interven-
tions to be conducted. This is inherently reliant on a
growing evidence base of the efficacy of such interventions
which ideally would incorporate economic evaluation
alongside such efforts. Modeling could then be utilised to
predict longer term cost-effectiveness over the life course
and OA disease progression; this would require explicit
statements of the assumptions about maintenance of
program effect and their testing in sensitivity analysis.
Economic evaluation in addressing obesity in OA should
ideally adopt a societal perspective given that both costs
and benefits may be incurred beyond the heath-care
sector and where possible, an incremental cost per QALY
should be reported to provide comparison across disease
areas.
The notion of intervening to alter disease progression,
delay, avoid or reduce complications post TJA by address-
ing obesity explicitly is, prima facie, likely to have both
downstream economic and health benefits to healthcare
systems, individuals and society as a whole. In practice,
guidelines identify the need to focus on obesity in the
management of OA, however it is evident that there is a
lack of data both from an efficacy and cost-effectiveness
perspective to support and to guide to whom, how and
when this should be conducted and whether it should be
explicitly incorporated into clinical pathways and public
health practice. More research is therefore warranted in
order to guide clinicians, funders, decision makers and
patients alike.
Conclusion
Overall, this review has demonstrated that while the pres-
ence of obesity in OA populations, and in particular severe
obesity, has been shown to have significant health and eco-
nomic impacts, there is a dearth of evidence from an eco-
nomic perspective to guide resource decisions about
whether addressing obesity explicitly is considered value for
money.
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